EZETIMIBE OR STATIN MONOTHERAPY VS CO-ADMINISTRATION IN ETHNIC GROUPS

该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 本研究的目的是在同等数量的黑人和白色非西班牙裔男性中比较依齐米贝或辛伐他汀单药治疗和两种药物联合治疗诱导的LDL胆固醇百分比变化。 依折麦布是一种阻断固醇吸收的药物，辛伐他汀阻断肝脏胆固醇生物合成。 待检验的假设是，黑人可能比他汀类药物对依齐替米贝降低LDL更敏感，因为黑人胆固醇产量低。 这是一项为期26周的随机化、双盲、安慰剂对照、4阶段、交叉研究，包括3天筛选期、2周单盲安慰剂导入期和4个6周双盲治疗期。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to compare the percent change in LDL cholesterol induced by ezitimibe or simvastatin monotherapy and by co-administration of both agents in anequal number of black and White non-Hispanic men. Ezetimibe is a drug that blocks sterol absorption and simvastatin block hepatic cholesterol biosynthesis. The hypothesis to be tested is that Blacks are likely to be more responsive to LDL lowering by ezitimibe than statins because Blacks have a low production of cholesterol. This will be a randomized, double-blind, placebo-controlled, 4-period, crossover study of 26 wekks duration comprising a 3-day screening period; a 2-week, single-blind placebo run-in period; and four 6-week, double-blind treatment periods.